hVIVO (LON:HVO) Stock Passes Below Fifty Day Moving Average – Should You Sell?

hVIVO plc (LON:HVO)’s share price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 8.65 ($0.12) and traded as low as GBX 6.80 ($0.09). hVIVO shares last traded at GBX 6.80 ($0.09), with a volume of 4,562,857 shares traded.

Analyst Ratings Changes

A number of research firms have recently commented on HVO. Shore Capital lowered their price target on hVIVO from GBX 35 to GBX 25 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Peel Hunt restated an “add” rating and set a GBX 21 price objective on shares of hVIVO in a research report on Tuesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, hVIVO currently has a consensus rating of “Buy” and an average target price of GBX 23.

hVIVO Price Performance

The firm has a market cap of £46.73 million, a P/E ratio of 8.83 and a beta of 0.97. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The business has a 50-day moving average of GBX 8.65 and a two-hundred day moving average of GBX 11.58.

hVIVO (LON:HVO) last issued its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, sell-side analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.